Sponsors (12)
The bill clarifies and standardizes federal tax treatment for activities involving controlled substances—reducing enforcement uncertainty—but entrenches a prohibition on deductions (and thus higher federal tax burdens) for state-legal marijuana businesses and offers no retroactive relief.
Businesses engaging in activities involving federally controlled substances, and the IRS and tax courts, gain clearer statutory guidance on which business expenses are nondeductible, reducing audit uncertainty and promoting more consistent tax administration.
Businesses operating legally under state marijuana laws remain barred from claiming federal deductions for ordinary business expenses, increasing their federal tax liabilities.
Higher effective federal tax burdens on these businesses will reduce profitability and may lead to higher consumer prices, slower market entry, and reduced investment in the state-legal cannabis industry.
The change applies prospectively only, so past taxpayers cannot claim refunds for prior years even if they relied on different interpretations, denying retroactive relief to businesses that previously paid under uncertainty.
Based on analysis of 2 sections of legislative text.
Amends the tax code to explicitly bar marijuana businesses from claiming deductions or credits under IRC 280E and retains the prohibition for Schedule I and II substances.
Amends the Internal Revenue Code to explicitly prohibit marijuana businesses from claiming business deductions or credits under IRC 280E, and keeps the existing prohibition for other Schedule I and II controlled substances. The change applies to amounts paid or incurred after enactment in taxable years ending after that date, increasing federal tax exposure for firms that produce, distribute, or sell marijuana.
Introduced February 21, 2025 by Jodey Cook Arrington · Last progress February 21, 2025